Monoclonal antibodies in the treatment of ovarian cancer.
Monoclonal antibody application in ovarian cancer started eight years after the discovery of Köhler and Milstein, with the studies of Bast et al. which led to the introduction of CA 125 antigen estimation to everyday clinical routine. At present, monoclonal antibodies serve as a therapeutic tool for variable targets with the potential to be applied in multiple clinical situations. In the coming decade, the drug market is likely to be flooded with monoclonal antibodies. Most of the available monoclonal antibodies will be produced in bioreactors, using transgenic plants or transgenic animals. Apart from mouse antibodies, chimeric, humanised or human antibodies, oncology will certainly employ chimeric structures with antibody fragments built into the structures of receptors or growth factors. Irrespective of their origin, they will constitute an integral part of medical practice.
Markowska
J
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012680:Sensitivity and Specificity; D015996:Survival Rate; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal